Evidence map›Paper›PMID 40847999›Full record

ArticleACS synthetic biology2025

Engineering the Tobacco Etch Virus Protease toward a Platform for Traceless Cleavage Using Distal Site Prediction and Smart Library Design.

Martijn P Bemelmans, Bach-Ngan Wetzel, Florian G Neusius, Florian Tieves, Christian Schwarz, Ivan Mateljak, Katarzyna Świderek, Vicent Moliner, Miguel Alcalde, Volker Sieber

Abstract read
In one paragraph

Article in ACS synthetic biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Martijn P BemelmansSynBiofoundry@TUM, Technical University of Munich, Schulgasse 16, 94315 Straubing, Germany.ORCID 0000-0002-4423-8956
Bach-Ngan WetzelNUMAFERM GmbH, Merowingerplatz 1a, 40225 Düsseldorf, Germany.
Florian G NeusiusNUMAFERM GmbH, Merowingerplatz 1a, 40225 Düsseldorf, Germany.
Florian TievesNUMAFERM GmbH, Merowingerplatz 1a, 40225 Düsseldorf, Germany.
Christian SchwarzNUMAFERM GmbH, Merowingerplatz 1a, 40225 Düsseldorf, Germany.
Ivan MateljakEvoenzyme S.L., Parque Cientifico de Madrid, 28049, Madrid, Spain.ORCID 0000-0002-8848-1587
Katarzyna ŚwiderekBiocomp Group, Institute of Advanced Materials (INAM), Universitat Jaume I, 12071 Castello, Spain.ORCID 0000-0002-7528-1551
Vicent MolinerBiocomp Group, Institute of Advanced Materials (INAM), Universitat Jaume I, 12071 Castello, Spain.ORCID 0000-0002-3665-3391
Miguel AlcaldeInstitute of Catalysis, CSIC, 28049 Madrid, Spain.ORCID 0000-0001-6780-7616
Volker SieberSynBiofoundry@TUM, Technical University of Munich, Schulgasse 16, 94315 Straubing, Germany.ORCID 0000-0001-5458-9330

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein tags are vital in biochemical engineering but must be removed from target molecules to prevent compromising effects. Most industrial applications use Tobacco Etch Virus protease (TEVp) for this purpose. However, selectivity at the P1' position of its recognition site requires N-terminal addition of glycine or serine to noncanonical targets. This residue remains after cleavage, preventing the retrieval of customized peptides with native N-termini. Here, we engineered a TEVp variant (TEVp-C1) with unlocked promiscuity informed by graph network analysis to identify distal positions of influence and smart library design. Compared to state-of-the-art, TEVp-C1 exhibits significantly improved cleavage for 15 of the 20 natural amino acids at P1' against Switchtag-Teriparatide substrates. Moreover, TEVp-C1 displayed enhanced activity against fluorogenic peptide substrates for five of the most disfavored residues at P1'. Mechanistic analysis revealed that the introduced mutations facilitate the proton transfer step. Altogether, the results highlight the potential of TEVp-C1 as a protease platform for traceless cleavage and demonstrate the feasibility of using tools for the prediction of allosteric interactions to engineer substrate specificities of enzymes via mutations at distal amino acid positions.

Indexed as

EndopeptidasesPotyvirusProtein EngineeringPeptide LibrarySubstrate SpecificityEndopeptidasesPeptide LibraryTEV proteasedistal site mutagenesisgraph network analysisprotein engineeringTEV proteasetraceless peptide cleavage

Identifiers

PMID40847999
PMCPMC12455634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.